Triple-negative breast cancer (TNBC) is one of the most aggressive and treatment-resistant subtypes of breast cancer, accounting for 15% to 20% of all cases. Unlike other breast cancers, TNBC lacks targetable receptors, leaving patients dependent largely on chemotherapy, with limited treatment options.
